Nanoparticles and microparticles for skin drug delivery

Advanced Drug Delivery Reviews

Volumn 63, Issue 6, 2011, Pages 470-491

  Prow, Tarl W ^a   Grice, Jeffrey E ^a   Lin, Lynlee L ^a   Faye, Rokhaya ^a   Butler, Margaret ^a   Becker, Wolfgang ^c   Wurm, Elisabeth M T ^a   Yoong, Corinne ^a   Robertson, Thomas A ^a,b   Soyer, H Peter ^a   Roberts, Michael S ^a,b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^c BECKER AND HICKL GMBH   (Germany)

Author keywords

Drug delivery; Nanoparticle; Percutaneous penetration; Skin; Topical; Transdermal delivery

Indexed keywords

ANTI-MICROBIAL ACTIVITY; CLINICAL DATA; ENABLING TECHNOLOGIES; FUTURE DIRECTIONS; HAIR FOLLICLES; HUMAN SKIN; LIPID CARRIERS; METAL NANOPARTICLES; MICRO-PARTICLES; NANO-EMULSIONS; PARTICLE PENETRATION; PARTICLE TECHNOLOGY; PERCUTANEOUS PENETRATION; PHYSICAL BARRIERS; SKIN CANCERS; SOLID LIPID NANOPARTICLES; STRATUM CORNEUM; SYSTEMIC DISEASE; TOPICAL; TRANSDERMAL DELIVERY;

DRUG DELIVERY;

NANOPARTICLES;

ACECLOFENAC; ALPHA TOCOPHEROL; ANTIINFECTIVE AGENT; BETAMETHASONE VALERATE; CAPSAICIN; CELECOXIB; CLOBETASOL PROPIONATE; CORTICOSTERONE; FLUFENAMIC ACID; FLURBIPROFEN; FULLERENE; GLYCYRRHETINIC ACID; ISOTRETINOIN; KETOPROFEN; METAL NANOPARTICLE; NANOPARTICLE; NAPROXEN; NIMESULIDE; PREDNICARBATE; QUANTUM DOT; RETINOIC ACID; RETINOID DERIVATIVE; RETINOL; RETINOL PALMITATE; SILVER NANOPARTICLE; SOLID LIPID NANOPARTICLE; SUNSCREEN; TRIPTOLIDE; UNINDEXED DRUG; ZINC OXIDE;

ACNE; ANTIINFLAMMATORY ACTIVITY; DIABETIC NEUROPATHY; DRUG ADMINISTRATION ROUTE; DRUG DELIVERY SYSTEM; DRUG MECHANISM; DRUG PENETRATION; DRUG UPTAKE; ENZYME INHIBITION; EPIDERMIS; HAIR FOLLICLE; HUMAN; MOLECULAR INTERACTION; NANOEMULSION; NANOTECHNOLOGY; PAIN; PARTICLE SIZE; PHOTOAGING; PRIORITY JOURNAL; REVIEW; SKIN DISEASE; SKIN PERMEABILITY; SKIN STRUCTURE; STRATUM CORNEUM; SYSTEMIC DISEASE; TIGHT JUNCTION;

ADMINISTRATION, CUTANEOUS; ANIMALS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HUMANS; MICROSPHERES; NANOPARTICLES; SKIN;

EID: 79953198946     PISSN: 0169409X     EISSN: 0169409X     Source Type: Journal    
DOI: 10.1016/j.addr.2011.01.012     Document Type: Review

References (257)

1. Roberts M.S., Cross S.E., Pellett M.A. Skin transport. Dermatological and Transdermal Formulations 2002, 89-195. Marcel Dekker, Inc., New York, NY. K.A. Walters (Ed.).
2. Norlen L. The physical structure of the skin barrier. Dermal Absorption and Toxicity Assessment 2008, 37-68. Informa Healthcare USA, Inc., New York, NY. M.S. Roberts, K.A. Walters (Eds.).
3. Monteiro-Riviere N.A., Baroli B. Nanomaterial penetration. Toxicology of the Skin 2010, 333-346. Informa Healthcare USA, Inc., New York, NY. N.A. Monteiro-Riviere (Ed.).
4. Muller R.H., Mehnert W., Souto E.B. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) for dermal delivery. Percutaneous Absorption. Drugs-Cosmetics-Mechanisms-Methodology 2005, 719-738. Taylor & Francis Group, LLC, Boca Raton, FL. R.L. Bronaugh, H.I. Maibach (Eds.).
5. Roy S.D., Gutierrez M., Flynn G.L., Cleary G.W. Controlled transdermal delivery of fentanyl: characterizations of pressure-sensitive adhesives for matrix patch design. J. Pharm. Sci. 1996, 85:491-495.
6. FAQs: Nanotechnology. National Nanotechnology Initiative 2010.
7. Lövestam G., Rauscher H., Roebben G., Klüttgen B.S., Gibson N., Putaud J.P., Stamm H. Considerations on a definition of nanomaterial for regulatory purposes. JCR Reference Reports, Luxembourg 2010, 40. J.R. Centre (Ed.).
8. Baroli B. Penetration of nanoparticles and nanomaterials in the skin: fiction or reality?. J. Pharm. Sci. 2010, 99:21-50.
9. Schneider M., Stracke F., Hansen S., Schaefer U.F. Nanoparticles and their interactions with the dermal barrier. Dermatoendocrinology 2009, 1:197-206.
10. Prow T.W., Chen X., Prow N.A., Fernando G.J., Tan C.S., Raphael A.P., Chang D., Ruutu M.P., Jenkins D.W., Pyke A., Crichton M.L., Raphaelli K., Goh L.Y., Frazer I.H., Roberts M.S., Gardner J., Khromykh A.A., Suhrbier A., Hall R.A., Kendall M.A. Nanopatch-targeted skin vaccination against West Nile Virus and Chikungunya Virus in mice. Small 2010, 6:1776-1784.
11. Tian J., Wong K.K., Ho C.M., Lok C.N., Yu W.Y., Che C.M., Chiu J.F., Tam P.K. Topical delivery of silver nanoparticles promotes wound healing. ChemMedChem 2007, 2:129-136.
12. NCT01125215, Capsaicin Nanoparticle in Patient With Painful Diabetic Neuropathy 2009.
13. Erdogan S. Liposomal nanocarriers for tumor imaging. J. Biomed. Nanotechnol. 2009, 5:141-150.
14. Liang C.H., Chou T.H. Effect of chain length on physicochemical properties and cytotoxicity of cationic vesicles composed of phosphatidylcholines and dialkyldimethylammonium bromides. Chem. Phys. Lipids 2009, 158:81-90.
15. Roberts M.S. The latest science (including safety) on nanotechnology and skin penetration. FDA public hearing on the science of nanomaterials, Washington, D.C. 2006.
16. Nohynek G.J., Lademann J., Ribaud C., Roberts M.S. Grey goo on the skin? Nanotechnology, cosmetic and sunscreen safety. Crit. Rev. Toxicol. 2007, 37:251-277.
17. Dubina M., Goldenberg G. Viral-associated nonmelanoma skin cancers: a review. Am. J. Dermatopathol. 2009, 31:561-573.
18. Carmona-Ribeiro A.M. Biomimetic nanoparticles: preparation, characterization and biomedical applications. Int. J. Nanomedicine 2010, 5:249-259.
19. Bryan J.T., Brown D.R. Transmission of human papillomavirus type 11 infection by desquamated cornified cells. Virology 2001, 281:35-42.
20. Muller R.H., Petersen R.D., Hommoss A., Pardeike J. Nanostructured lipid carriers (NLC) in cosmetic dermal products. Adv. Drug Deliv. Rev. 2007, 59:522-530.
21. On regulatory aspects of nanomaterials, in, Scientific Committee on Consumer Products, European Commission (2008).
22. Ryman-Rasmussen J.P., Riviere J.E., Monteiro-Riviere N.A. Variables influencing interactions of untargeted quantum dot nanoparticles with skin cells and identification of biochemical modulators. Nano Lett. 2007, 7:1344-1348.
23. Baroli B., Ennas M.G., Loffredo F., Isola M., Pinna R., Lopez-Quintela M.A. Penetration of metallic nanoparticles in human full-thickness skin. J. Invest. Dermatol. 2007, 127:1701-1712.
24. Prow T., Rijnbrand R., Leary J.F. Development of a novel targeted nanoparticle gene therapy strategy for the treatment of hepatitis C virus infection. Cytometry 2002, 138-138.
25. Prow T.W., Kotov N.A., Lvov Y.M., Rijnbrand R., Leary J.F. Nanoparticles, molecular biosensors, and multispectral confocal microscopy. J. Mol. Histol. 2004, 35:555-564.
26. Prow T.W., Rose W.A., Wang N., Recce L.M., Lvov Y., Leary J.F. Biosensor-controlled gene therapy/drug delivery with nanoparticles for nanomedicine. Advanced Biomedical and Clinical Diagnostic Systems III 2005, 5692:199-208. (392).
27. Prow T., Grebe R., Merges C., Smith J., McLeod D., Leary J., Lutty G. Nanoparticle tethered antioxidant response element as a biosensor for oxygen induced toxicity in retinal endothelial cells. Mol. Vis. 2006, 12:616-625.
28. Prow T., Smith J.N., Grebe R., Salazar J.H., Wang N., Kotov N., Lutty G., Leary J. Construction, gene delivery, and expression of DNA tethered nanoparticles. Mol. Vis. 2006, 12:606-615.
29. Prow T.W., Bhutto I., Grebe R., Uno K., Merges C., Mcleod D.S., Lutty G.A. Nanoparticle-delivered biosensor for reactive oxygen species in diabetes. Vis. Res. 2008, 48:478-485.
30. Prow T.W., Bhutto I., Kim S.Y., Grebe R., Merges C., McLeod D.S., Uno K., Mennon M., Rodriguez L., Leong K., Lutty G.A. Ocular nanoparticle toxicity and transfection of the retina and retinal pigment epithelium. Nanomed. Nanotechnol. Biol. Med. 2008, 4:340-349.
31. Prow T.W., Chen X., Crichton M., Tiwari Y., Gradassi F., Raphelli K., Mahony D., Fernando G., Roberts M.S., Kendall M.A.F. Targeted epidermal delivery of vaccines from coated micro-nanoprojection patches. 2008 International Conference on Nanoscience and Nanotechnology 2008, 125-128. (240).
32. Chen X.F., Prow T.W., Crichton M.L., Jenkins D.W.K., Roberts M.S., Frazer I.H., Fernando G.J.P., Kendall M.A.F. Dry-coated microprojection array patches for targeted delivery of immunotherapeutics to the skin. J. Control. Release 2009, 139:212-220.
33. Geusens B., Sanders N., Prow T., Van Gele M., Lambert J. Cutaneous short-interfering RNA therapy. Expert Opin. Drug Deliv. 2009, 6:1333-1349.
34. Crichton M.L., Ansaldo A., Chen X.F., Prow T.W., Fernando G.J.P., Kendall M.A.F. The effect of strain rate on the precision of penetration of short densely-packed microprojection array patches coated with vaccine. Biomaterials 2010, 31:4562-4572.
35. Fernando G.J.P., Chen X.F., Prow T.W., Crichton M.L., Fairmaid E.J., Roberts M.S., Frazer I.H., Brown L.E., Kendall M.A.F. Potent immunity to low doses of influenza vaccine by probabilistic guided micro-targeted skin delivery in a mouse model. PLoS ONE 2010, 5.
36. Geusens B., Van Gele M., Braat S., De Smedt S.C., Stuart M.C.A., Prow T., Sanchez W., Roberts M.S., Sanders N.N., Lambert J. Flexible nanosomes (SECosomes) enable efficient siRNA delivery in cultured primary skin cells and in viable epidermis of ex-vivo human skin. J. Pharm. Pharmacol. 2010, 62:788-788.
37. Cross S.E., Innes B., Roberts M.S., Tsuzuki T., Robertson T.A., McCormick P. Human skin penetration of sunscreen nanoparticles: in-vitro assessment of a novel micronized zinc oxide formulation. Skin Pharmacol. Physiol. 2007, 20:148-154.
38. Nohynek G.J., Dufour E.K., Roberts M.S. Nanotechnology, cosmetics and the skin: is there a health risk?. Skin Pharmacol. Physiol. 2008, 21:136-149.
39. Roberts M.S., Roberts M.J., Robertson T.A., Sanchez W., Thorling C., Zou Y., Zhao X., Becker W., Zvyagin A.V. In vitro and in vivo imaging of xenobiotic transport in human skin and in the rat liver. J. Biophotonics 2008, 1:478-493.
40. Zvyagin A.V., Zhao X., Gierden A., Sanchez W., Ross J.A., Roberts M.S. Imaging of zinc oxide nanoparticle penetration in human skin in vitro and in vivo. J. Biomed. Opt. 2008, 13:064031.
41. Oberdorster G., Maynard A., Donaldson K., Castranova V., Fitzpatrick J., Ausman K., Carter J., Karn B., Kreyling W., Lai D., Olin S., Monteiro-Riviere N., Warheit D., Yang H. Principles for characterizing the potential human health effects from exposure to nanomaterials: elements of a screening strategy. Part. Fibre Toxicol. 2005, 2:8.
42. Rouse J.G., Yang J., Barron A.R., Monteiro-Riviere N.A. Fullerene-based amino acid nanoparticle interactions with human epidermal keratinocytes. Toxicol. In Vitro 2006, 20:1313-1320.
43. Wei C., Lyubchenko Y.L., Ghandehari H., Hanes J., Stebe K.J., Mao H.Q., Haynie D.T., Tomalia D.A., Foldvari M., Monteiro-Riviere N., Simeonova P., Nie S., Mori H., Gilbert S.P., Needham D. New technology and clinical applications of nanomedicine: highlights of the second annual meeting of the American Academy of Nanomedicine (Part I). Nanomedicine 2006, 2:253-263.
44. Witzmann F.A., Monteiro-Riviere N.A. Multi-walled carbon nanotube exposure alters protein expression in human keratinocytes. Nanomedicine 2006, 2:158-168.
45. Xia X.R., Monteiro-Riviere N.A., Riviere J.E. Trace analysis of fullerenes in biological samples by simplified liquid-liquid extraction and high-performance liquid chromatography. J. Chromatogr. A 2006, 1129:216-222.
46. Balbus J.M., Maynard A.D., Colvin V.L., Castranova V., Daston G.P., Denison R.A., Dreher K.L., Goering P.L., Goldberg A.M., Kulinowski K.M., Monteiro-Riviere N.A., Oberdorster G., Omenn G.S., Pinkerton K.E., Ramos K.S., Rest K.M., Sass J.B., Silbergeld E.K., Wong B.A. Meeting report: hazard assessment for nanoparticles-report from an interdisciplinary workshop. Environ. Health Perspect. 2007, 115:1654-1659.
47. Lee H.A., Imran M., Monteiro-Riviere N.A., Colvin V.L., Yu W.W., Riviere J.E. Biodistribution of quantum dot nanoparticles in perfused skin: evidence of coating dependency and periodicity in arterial extraction. Nano Lett. 2007, 7:2865-2870.
48. Rouse J.G., Yang J., Ryman-Rasmussen J.P., Barron A.R., Monteiro-Riviere N.A. Effects of mechanical flexion on the penetration of fullerene amino acid-derivatized peptide nanoparticles through skin. Nano Lett. 2007, 7:155-160.
49. Ryman-Rasmussen J.P., Riviere J.E., Monteiro-Riviere N.A. Surface coatings determine cytotoxicity and irritation potential of quantum dot nanoparticles in epidermal keratinocytes. J. Invest. Dermatol. 2007, 127:143-153.
50. Karakoti A.S., Monteiro-Riviere N.A., Aggarwal R., Davis J.P., Narayan R.J., Self W.T., McGinnis J., Seal S. Nanoceria as antioxidant: synthesis and biomedical applications. JOM 1989, 60(2008):33-37.
51. Rouse J.G., Haslauer C.M., Loboa E.G., Monteiro-Riviere N.A. Cyclic tensile strain increases interactions between human epidermal keratinocytes and quantum dot nanoparticles. Toxicol. In Vitro 2008, 22:491-497.
52. Zhang L.W., Monteiro-Riviere N.A. Assessment of quantum dot penetration into intact, tape-stripped, abraded and flexed rat skin. Skin Pharmacol. Physiol. 2008, 21:166-180.
53. Zhang L.W., Yu W.W., Colvin V.L., Monteiro-Riviere N.A. Biological interactions of quantum dot nanoparticles in skin and in human epidermal keratinocytes. Toxicol. Appl. Pharmacol. 2008, 228:200-211.
54. Adiga S.P., Jin C., Curtiss L.A., Monteiro-Riviere N.A., Narayan R.J. Nanoporous membranes for medical and biological applications. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 2009, 1:568-581.
55. Lee H.A., Leavens T.L., Mason S.E., Monteiro-Riviere N.A., Riviere J.E. Comparison of quantum dot biodistribution with a blood-flow-limited physiologically based pharmacokinetic model. Nano Lett. 2009, 9:794-799.
56. Monteiro-Riviere N.A., Inman A.O., Zhang L.W. Limitations and relative utility of screening assays to assess engineered nanoparticle toxicity in a human cell line. Toxicol. Appl. Pharmacol. 2009, 234:222-235.
57. Zhang L.W., Monteiro-Riviere N.A. Mechanisms of quantum dot nanoparticle cellular uptake. Toxicol. Sci. 2009, 110:138-155.
58. Zhang L.W., Yang J., Barron A.R., Monteiro-Riviere N.A. Endocytic mechanisms and toxicity of a functionalized fullerene in human cells. Toxicol. Lett. 2009, 191:149-157.
59. Leavens T.L., Xia X.R., Lee H.A., Monteiro-Riviere N.A., Brooks J.D., Riviere J.E. Evaluation of perfused porcine skin as a model system to quantitate tissue distribution of fullerene nanoparticles. Toxicol. Lett. 2010, 197:1-6.
60. Monteiro-Riviere N.A., Oldenburg S.J., Inman A.O. Interactions of aluminum nanoparticles with human epidermal keratinocytes. J. Appl. Toxicol. 2010, 30:276-285.
61. Samberg M.E., Oldenburg S.J., Monteiro-Riviere N.A. Evaluation of silver nanoparticle toxicity in skin in vivo and keratinocytes in vitro. Environ. Health Perspect. 2010, 118:407-413.
62. Xia X.R., Monteiro-Riviere N.A., Riviere J.E. An index for characterization of nanomaterials in biological systems. Nat. Nanotechnol. 2010, 5:671-675.
63. Xia X.R., Monteiro-Riviere N.A., Riviere J.E. Intrinsic biological property of colloidal fullerene nanoparticles (nC60): lack of lethality after high dose exposure to human epidermal and bacterial cells. Toxicol. Lett. 2010, 197:128-134.
64. Xia X.R., Monteiro-Riviere N.A., Riviere J.E. Skin penetration and kinetics of pristine fullerenes (C60) topically exposed in industrial organic solvents. Toxicol. Appl. Pharmacol. 2010, 242:29-37.
65. Borm P.J., Robbins D., Haubold S., Kuhlbusch T., Fissan H., Donaldson K., Schins R., Stone V., Kreyling W., Lademann J., Krutmann J., Warheit D., Oberdorster E. The potential risks of nanomaterials: a review carried out for ECETOC. Part. Fibre Toxicol. 2006, 3:11.
66. Graf C., Meinke M., Gao Q., Hadam S., Raabe J., Sterry W., Blume-Peytavi U., Lademann J., Ruhl E., Vogt A. Qualitative detection of single submicron and nanoparticles in human skin by scanning transmission X-ray microscopy. J. Biomed. Opt. 2009, 14:021015.
67. Jung S., Patzelt A., Otberg N., Thiede G., Sterry W., Lademann J. Strategy of topical vaccination with nanoparticles. J. Biomed. Opt. 2009, 14:021001.
68. Lademann J., Knorr F., Richter H., Blume-Peytavi U., Vogt A., Antoniou C., Sterry W., Patzelt A. Hair follicles-an efficient storage and penetration pathway for topically applied substances. Summary of recent results obtained at the Center of Experimental and Applied Cutaneous Physiology, Charite-Universitatsmedizin Berlin, Germany. Skin Pharmacol. Physiol. 2008, 21:150-155.
69. Lademann J., Meinke M., Sterry W., Patzelt A. How safe are nanoparticles?. Hautarzt 2009, 60:305-309.
70. Lademann J., Patzelt A., Richter H., Antoniou C., Sterry W., Knorr F. Determination of the cuticula thickness of human and porcine hairs and their potential influence on the penetration of nanoparticles into the hair follicles. J. Biomed. Opt. 2009, 14:021014.
71. Lademann J., Richter H., Schaefer U.F., Blume-Peytavi U., Teichmann A., Otberg N., Sterry W. Hair follicles - a long-term reservoir for drug delivery. Skin Pharmacol. Physiol. 2006, 19:232-236.
72. Lademann J., Richter H., Teichmann A., Otberg N., Blume-Peytavi U., Luengo J., Weiss B., Schaefer U.F., Lehr C.M., Wepf R., Sterry W. Nanoparticles-an efficient carrier for drug delivery into the hair follicles. Eur. J. Pharm. Biopharm. 2007, 66:159-164.
73. Popov A.P., Haag S., Meinke M., Lademann J., Priezzhev A.V., Myllyla R. Effect of size of TiO2 nanoparticles applied onto glass slide and porcine skin on generation of free radicals under ultraviolet irradiation. J. Biomed. Opt. 2009, 14:021011.
74. Popov A.P., Lademann J., Priezzhev A.V., Myllyla R. Effect of size of TiO2 nanoparticles embedded into stratum corneum on ultraviolet-A and ultraviolet-B sun-blocking properties of the skin. J. Biomed. Opt. 2005, 10:064037.
75. Vogt A., Combadiere B., Hadam S., Stieler K.M., Lademann J., Schaefer H., Autran B., Sterry W., Blume-Peytavi U. 40nm, but not 750 or 1,500nm, nanoparticles enter epidermal CD1a+ cells after transcutaneous application on human skin. J. Invest. Dermatol. 2006, 126:1316-1322.
76. Warheit D.B., Borm P.J., Hennes C., Lademann J. Testing strategies to establish the safety of nanomaterials: conclusions of an ECETOC workshop. Inhal. Toxicol. 2007, 19:631-643.
77. Alvarez-Roman R., Naik A., Kalia Y.N., Guy R.H., Fessi H. Enhancement of topical delivery from biodegradable nanoparticles. Pharm. Res. 2004, 21:1818-1825.
78. Alvarez-Roman R., Naik A., Kalia Y.N., Guy R.H., Fessi H. Skin penetration and distribution of polymeric nanoparticles. J. Control. Release 2004, 99:53-62.
79. Wu X., Griffin P., Price G.J., Guy R.H. Preparation and in vitro evaluation of topical formulations based on polystyrene-poly-2-hydroxyl methacrylate nanoparticles. Mol. Pharm. 2009, 6:1449-1456.
80. Wu X., Landfester K., Musyanovych A., Guy R.H. Disposition of charged nanoparticles after their topical application to the skin. Skin Pharmacol. Physiol. 2010, 23:117-123.
81. Wu X., Price G.J., Guy R.H. Disposition of nanoparticles and an associated lipophilic permeant following topical application to the skin. Mol. Pharm. 2009, 6:1441-1448.
82. Roberts M.S., Dancik Y., Prow T.W., Thorling C.A., Li L.L., Grice J.E., Robertson T.A., K.K., Becker W. Non-invasive imaging of skin physiology and percutaneous penetration using fluorescence spectral and lifetime imaging with multiphoton and confocal microscopy. Eur. J. Pharm. Biopharm. 2011, 77:469-488.
83. Robertson T.A., Sanchez W.Y., Roberts M.S. Are commercially available nanoparticles safe when applied to the skin?. J. Biomed. Nanotechnol. 2010, 6:452-468.
84. Roberts M.S., Walters K.A. Human skin morphology and dermal absorption. Dermal Absorption and Toxicity Assessment 2008, 1-15. Informa Healthcare, New York. M.S. Roberts, K.A. Walters (Eds.).
85. Monteiro-Riviere N.A. Structure and function of skin. Toxicology of the Skin 2010, 1-18. Informa Healthcare USA, Inc., New York. N.A. Monteiro-Riviere (Ed.).
86. Bouwstra J.A., Honeywell-Nguyen P.L. Skin structure and mode of action of vesicles. Adv. Drug Deliv. Rev. 2002, 54(Suppl 1):S41-S55.
87. Elias P.M., Friend D.S. The permeability barrier in mammalian epidermis. J. Cell Biol. 1975, 65:180-191.
88. Elias P.M., Menon G.K. Structural and lipid biochemical correlates of the epidermal permeability barrier. Adv. Lipid Res. 1991, 24:1-26.
89. Michaels A.S., Chandrasekaran S.K., Shaw J.E. Drug permeation through human skin: theory and in vitro experimental measurement. AlChE J. 1975, 21:985-986.
90. Caubet C., Jonca N., Brattsand M., Guerrin M., Bernard D., Schmidt R., Egelrud T., Simon M., Serre G. Degradation of corneodesmosome proteins by two serine proteases of the kallikrein family, SCTE/KLK5/hK5 and SCCE/KLK7/hK7. J. Invest. Dermatol. 2004, 122:1235-1244.
91. Tregear R.T. The permeability of mammalian skin to ions. J. Invest. Dermatol. 1966, 46:16-23.
92. Potts R.O., Guy R.H. A predictive algorithm for skin permeability: the effects of molecular size and hydrogen bond activity. Pharm. Res. 1995, 12:1628-1633.
93. van der Merwe D., Brooks J.D., Gehring R., Baynes R.E., Monteiro-Riviere N.A., Riviere J.E. A physiologically based pharmacokinetic model of organophosphate dermal absorption. Toxicol. Sci. 2006, 89:188-204.
94. Reddy M.B., Guy R.H., Bunge A.L. Does epidermal turnover reduce percutaneous penetration?. Pharm. Res. 2000, 17:1414-1419.
95. Marks R. The stratum corneum barrier: the final frontier. J. Nutr. 2004, 134:2017S-2021S.
96. Scheuplein R.J. Mechanism of percutaneous adsorption. I. Routes of penetration and the influence of solubility. J. Invest. Dermatol. 1965, 45:334-346.
97. Albery W.J., Hadgraft J. Percutaneous absorption: theoretical description. J. Pharm. Pharmacol. 1979, 31:129-139.
98. Grice J.E., Ciotti S., Weiner N., Lockwood P., Cross S.E., Roberts M.S. Relative uptake of minoxidil into appendages and stratum corneum and permeation through human skin in vitro. J. Pharm. Sci. 2010, 99:712-718.
99. Wang T.F., Kasting G.B., Nitsche J.M. A multiphase microscopic diffusion model for stratum corneum permeability. II. Estimation of physicochemical parameters, and application to a large permeability database. J. Pharm. Sci. 2007, 96:3024-3051.
100. Roberts M.S., Walters K.A. Dermal Absorption and Toxicity Assessment 1998, Marcel Dekker, New York.
101. Lademann J., Richter H., Teichmann A., Otberg N., Blume-Peytavi U., Luengo J., Weiss B., Schaefer U.F., Lehr C.M., Wepf R., Sterry W. Nanoparticles-an efficient carrier for drug delivery into the hair follicles. Eur. J. Pharm. Biopharm. 2007, 66:159-164.
102. Schmid-Wendtner M.H., Korting H.C. The pH of the skin surface and its impact on the barrier function. Skin Pharmacol. Physiol. 2006, 19:296-302.
103. Hanson K.M., Behne M.J., Barry N.P., Mauro T.M., Gratton E., Clegg R.M. Two-photon fluorescence lifetime imaging of the skin stratum corneum pH gradient. Biophys. J. 2002, 83:1682-1690.
104. Krien P.M., Kermici M. Evidence for the existence of a self-regulated enzymatic process within the human stratum corneum-an unexpected role for urocanic acid. J. Invest. Dermatol. 2000, 115:414-420.
105. Le Texier L., Favre E., Redeuilh C., Blavet N., Bellahsene T., Dive G., Pirotzky E., Godfroid J.J. Structure-activity relationships in platelet-activating factor (PAF). 7. Tetrahydrofuran derivatives as dual PAF antagonists and acetylcholinesterase inhibitors. Synthesis and PAF-antagonistic activity. J. Lipid Mediat. Cell Signal. 1996, 13:189-205.
106. Janssens R., Communi D., Pirotton S., Samson M., Parmentier M., Boeynaems J.M. Cloning and tissue distribution of the human P2Y1 receptor. Biochem. Biophys. Res. Commun. 1996, 221:588-593.
107. Genotelle N., Lherm T., Gontier O., Le Gall C., Caen D. Right uncontrollable haemothorax revealing a liver injury with diaphragmatic rupture. Ann. Fr. Anesth. Rèanim. 2004, 23:831-834.
108. Li G.L., de Vries J.J., van Steeg T.J., van den Bussche H., Maas H.J., Reeuwijk H.J., Danhof M., Bouwstra J.A., van Laar T. Transdermal iontophoretic delivery of apomorphine in patients improved by surfactant formulation pretreatment. J. Control. Release 2005, 101:199-208.
109. Terreno E., Sanino A., Carrera C., Castelli D.D., Giovenzana G.B., Lombardi A., Mazzon R., Milone L., Visigalli M., Aime S. Determination of water permeability of paramagnetic liposomes of interest in MRI field. J. Inorg. Biochem. 2008, 102:1112-1119.
110. Seidenari S., Giusti G. Objective assessment of the skin of children affected by atopic dermatitis: a study of pH, capacitance and TEWL in eczematous and clinically uninvolved skin. Acta Derm. Venereol. 1995, 75:429-433.
111. Murphy R.J., Pristinski D., Migler K., Douglas J.F., Prabhu V.M. Dynamic light scattering investigations of nanoparticle aggregation following a light-induced pH jump. J. Chem. Phys. 2010, 132:194903.
112. Domenech J., Costa J.M. Photoelectrochemical oxidation of oxalate ion in aqueous dispersions of zinc-oxide. Photochem. Photobiol. 1986, 44:675-677.
113. Tso C.P., Zhung C.M., Shih Y.H., Tseng Y.M., Wu S.C., Doong R.A. Stability of metal oxide nanoparticles in aqueous solutions. Water Sci. Technol. 2010, 61:127-133.
114. Brandner J.M., Kief S., Grund C., Rendl M., Houdek P., Kuhn C., Tschachler E., Franke W.W., Moll I. Organization and formation of the tight junction system in human epidermis and cultured keratinocytes. Eur. J. Cell Biol. 2002, 81:253-263.
115. Langbein L., Grund C., Kuhn C., Praetzel S., Kartenbeck J., Brandner J.M., Moll I., Franke W.W. Tight junctions and compositionally related junctional structures in mammalian stratified epithelia and cell cultures derived therefrom. Eur. J. Cell Biol. 2002, 81:419-435.
116. Brandner J.M., McIntyre M., Kief S., Wladykowski E., Moll I. Expression and localization of tight junction-associated proteins in human hair follicles. Arch. Dermatol. Res. 2003, 295:211-221.
117. Kirschner N., Poetzl C., von den Driesch P., Wladykowski E., Moll I., Behne M.J., Brandner J.M. Alteration of tight junction proteins is an early event in psoriasis: putative involvement of proinflammatory cytokines. Am. J. Pathol. 2009, 175:1095-1106.
118. Watson R.E., Poddar R., Walker J.M., McGuill I., Hoare L.M., Griffiths C.E., O'Neill C.A. Altered claudin expression is a feature of chronic plaque psoriasis. J. Pathol. 2007, 212:450-458.
119. Guy R.H., Hadgraft J., Bucks D.A. Transdermal drug delivery and cutaneous metabolism. Xenobiotica 1987, 17:325-343.
120. Oesch F., Fabian E., Oesch-Bartlomowicz B., Werner C., Landsiedel R. Drug-metabolizing enzymes in the skin of man, rat, and pig. Drug Metab. Rev. 2007, 39:659-698.
121. Gulson B., McCall M., Korsch M., Gomez L., Casey P., Oytam Y., Taylor A., Kinsley L., Greenoak G. Small amounts of zinc from zinc oxide particles in sunscreens applied outdoors are absorbed through human skin. Toxicol. Sci. 2010, 118:140-149.
122. Gysler A., Kleuser B., Sippl W., Lange K., Korting H.C., Holtje H.D. Skin penetration and metabolism of topical glucocorticoids in reconstructed epidermis and in excised human skin. Pharm. Res. 1999, 16:1386-1391.
123. Bleasby K., Castle J.C., Roberts C.J., Cheng C., Bailey W.J., Sina J.F., Kulkarni A.V., Hafey M.J., Evers R., Johnson J.M., Ulrich R.G., Slatter J.G. Expression profiles of 50 xenobiotic transporter genes in humans and pre-clinical species: a resource for investigations into drug disposition. Xenobiotica 2006, 36:963-988.
124. Teskac K., Kristl J. The evidence for solid lipid nanoparticles mediated cell uptake of resveratrol. Int. J. Pharm. 2010, 390:61-69.
125. Dancik Y., Jepps O.G., Roberts M.S. Beyond stratum corneum. Dermal Absorption and Toxicity Assessment 2008, 209-250. Informa Healthcare USA, Inc., New York. M.S. Roberts, K.A. Walters (Eds.).
126. Dancik Y., Thompson C., Krishnan G., Roberts M.S. Cutaneous metabolism and active transport in transdermal drug delivery. Toxicology of the Skin 2010, 69-82. Informa Healthcare USA, Inc., New York, NY. N.A. Monteiro-Riviere (Ed.).
127. Essa E.A., Bonner M.C., Barry B.W. Human skin sandwich for assessing shunt route penetration during passive and iontophoretic drug and liposome delivery. J. Pharm. Pharmacol. 2002, 54:1481-1490.
128. Teichmann A., Otberg N., Jacobi U., Sterry W., Lademann J. Follicular penetration: development of a method to block the follicles selectively against the penetration of topically applied substances. Skin Pharmacol. Physiol. 2006, 19:216-223.
129. Lieb L.M., Ramachandran C., Egbaria K., Weiner N. Topical delivery enhancement with multilamellar liposomes into pilosebaceous units: I. In vitro evaluation using fluorescent techniques with the hamster ear model. J. Invest. Dermatol. 1992, 99:108-113.
130. Shim J., Seok Kang H., Park W.S., Han S.H., Kim J., Chang I.S. Transdermal delivery of mixnoxidil with block copolymer nanoparticles. J. Control. Release 2004, 97:477-484.
131. Lademann J., Weigmann H., Rickmeyer C., Barthelmes H., Schaefer H., Mueller G., Sterry W. Penetration of titanium dioxide microparticles in a sunscreen formulation into the horny layer and the follicular orifice. Skin Pharmacol. Appl. Skin Physiol. 1999, 12:247-256.
132. Marks R., Plunkett A., Merlin K., Jenner N. Atlas of common skin diseases in Australia, Department of Dermatology, St Vincent's Hospital, Melbourne 1999.
133. T.G.A. Department of Health and Ageing. A review of the scientific literature on the safety of nanoparticulate titanium dioxide or zinc oxide in sunscreens 2009.
134. Filipe P., Silva J.N., Silva R., de Castro J.L.C., Gomes M.M., Alves L.C., Santus R., Pinheiro T. Stratum corneum is an effective barrier to TiO2 and ZnO nanoparticle percutaneous absorption. Skin Pharmacol. Physiol. 2009, 22:266-275.
135. Hayden C.G., Roberts M.S., Benson H.A. Systemic absorption of sunscreen after topical application. Lancet 1997, 350:863-864.
136. Kuo T.R., Wu C.L., Hsu C.T., Lo W., Chiang S.J., Lin S.J., Dong C.Y., Chen C.C. Chemical enhancer induced changes in the mechanisms of transdermal delivery of zinc oxide nanoparticles. Biomaterials 2009, 30:3002-3008.
137. Szikszai Z., Kertesz Z., Bodnar E., Major I., Borbiro I., Kiss A.Z., Hunyadi J. Nuclear microprobe investigation of the penetration of ultrafine zinc oxide into intact and tape-stripped human skin. Nucl. Instrum. Meth. B 2010, 268:2160-2163.
138. Tinkle S.S., Antonini J.M., Rich B.A., Roberts J.R., Salmen R., DePree K., Adkins E.J. Skin as a route of exposure and sensitization in chronic beryllium disease. Environ. Health Perspect. 2003, 111:1202-1208.
139. Lekki J., Stachura Z., Dabros W., Stachura J., Menzel F., Reinert T., Butz T., Pallon J., Gontier E., Ynsa M.D., Moretto P., Kertesz Z., Szikszai Z., Kiss A.Z. On the follicular pathway of percutaneous uptake of nanoparticles: Ion microscopy and autoradiography studies. Nucl. Instrum. Methods Phys. Res. Sect. B 2007, 260:174-177.
140. Shakeel F., Baboota S., Ahuja A., Ali J., Aqil M., Shafiq S. Nanoemulsions as vehicles for transdermal delivery of aceclofenac. AAPS PharmSciTech 2007, 8:E104.
141. Sivaramakrishnan R., Nakamura C., Mehnert W., Korting H.C., Kramer K.D., Schäfer-Korting M. Glucocorticoid entrapment into lipid carriers-characterisation by parelectric spectroscopy and influence on dermal uptake. J. Control. Release 2004, 97:493-502.
142. Baboota S., Shakeel F., Ahuja A., Ali J., Shafiq S. Design, development and evaluation of novel nanoemulsion formulations for transdermal potential of celecoxib. Acta Pharm. 2007, 57:315-332.
143. Kalariya M., Padhi B.K., Chougule M., Misra A. Clobetasol propionate solid lipid nanoparticles cream for effective treatment of eczema: formulation and clinical implications. Indian J. Exp. Biol. 2005, 43:233-240.
144. Senyigit T., Sonvico F., Barbieri S., Ozer O., Santi P., Colombo P. Lecithin/chitosan nanoparticles of clobetasol-17-propionate capable of accumulation in pig skin. J. Control. Release 2010, 142:368-373.
145. Jensen L.B., Magnussson E., Gunnarsson L., Vermehren C., Nielsen H.M., Petersson K. Corticosteroid solubility and lipid polarity control release from solid lipid nanoparticles. Int. J. Pharm. 2010, 390:53-60.
146. Kuntsche J., Bunjes H., Fahr A., Pappinen S., Ronkko S., Suhonen M., Urtti A. Interaction of lipid nanoparticles with human epidermis and an organotypic cell culture model. Int. J. Pharm. 2008, 354:180-195.
147. Luengo J., Weiss B., Schneider M., Ehlers A., Stracke F., Konig K., Kostka K.H., Lehr C.M., Schaefer U.F. Influence of nanoencapsulation on human skin transport of flufenamic acid. Skin Pharmacol. Physiol. 2006, 19:190-197.
148. Santander-Ortega M.J., Stauner T., Loretz B., Ortega-Vinuesa J.L., Bastos-Gonzalez D., Wenz G., Schaefer U.F., Lehr C.M. Nanoparticles made from novel starch derivatives for transdermal drug delivery. J. Control. Release 2010, 141:85-92.
149. Bhaskar K., Anbu J., Ravichandiran V., Venkateswarlu V., Rao Y.M. Lipid nanoparticles for transdermal delivery of flurbiprofen: formulation, in vitro, ex vivo and in vivo studies. Lipids Health Dis. 2009, 8:6.
150. Jain S.K., Chourasia M.K., Masuriha R., Soni V., Jain A., Jain N.K., Gupta Y. Solid lipid nanoparticles bearing flurbiprofen for transdermal delivery. Drug Deliv. 2005, 12:207-215.
151. Puglia C., Rizza L., Drechsler M., Bonina F. Nanoemulsions as vehicles for topical administration of glycyrrhetic acid: characterization and in vitro and in vivo evaluation. Drug Deliv. 2010, 17:123-129.
152. Kim B.S., Won M., Lee K.M., Kim C.S. In vitro permeation studies of nanoemulsions containing ketoprofen as a model drug. Drug Deliv. 2008, 15:465-469.
153. Puglia C., Blasi P., Rizza L., Schoubben A., Bonina F., Rossi C., Ricci M. Lipid nanoparticles for prolonged topical delivery: an in vitro and in vivo investigation. Int. J. Pharm. 2008, 357:295-304.
154. Ganem-Quintanar A., Silva-Alvarez M., Alvarez-Roman R., Casas-Alancaster N., Cazares-Delgadillo J., Quintanar-Guerrero D. Design and evaluation of a self-adhesive naproxen-loaded film prepared from a nanoparticle dispersion. J. Nanosci. Nanotechnol. 2006, 6:3235-3241.
155. Puglia C., Bonina F., Rizza L., Cortesi R., Merlotti E., Drechsler M., Mariani P., Contado C., Ravani L., Esposito E. Evaluation of percutaneous absorption of naproxen from different liposomal formulations. J. Pharm. Sci. 2010, 99:2819-2829.
156. Alves M.P., Scarrone A.L., Santos M., Pohlmann A.R., Guterres S.S. Human skin penetration and distribution of nimesulide from hydrophilic gels containing nanocarriers. Int. J. Pharm. 2007, 341:215-220.
157. Maia C.S., Mehnert W., Schäfer-Korting M. Solid lipid nanoparticles as drug carriers for topical glucocorticoids. Int. J. Pharm. 2000, 196:165-167.
158. Maia S.C., Mehnert W., Schaller M., Korting H.C., Gysler A., Haberland A., Schäfer-Korting M. Drug targeting by solid lipid nanoparticles for dermal use. J. Drug Target. 2002, 10:489-495.
159. Mei Z., Chen H., Weng T., Yang Y., Yang X. Solid lipid nanoparticle and microemulsion for topical delivery of triptolide. Eur. J. Pharm. Biopharm. 2003, 56:189-196.
160. Ghouchi Eskandar N., Simovic S., Prestidge C.A. Nanoparticle coated submicron emulsions: sustained in-vitro release and improved dermal delivery of all-trans-retinol. Pharm. Res. 2009, 26:1764-1775.
161. Eskandar N.G., Simovic S., Prestidge C.A. Nanoparticle coated emulsions as novel dermal delivery vehicles. Curr. Drug Deliv. 2009, 6:367-373.
162. Castro G.A., Coelho A.L., Oliveira C.A., Mahecha G.A., Orefice R.L., Ferreira L.A. Formation of ion pairing as an alternative to improve encapsulation and stability and to reduce skin irritation of retinoic acid loaded in solid lipid nanoparticles. Int. J. Pharm. 2009, 381:77-83.
163. Mandawgade S.D., Patravale V.B. Development of SLNs from natural lipids: application to topical delivery of tretinoin. Int. J. Pharm. 2008, 363:132-138.
164. Castro G.A., Ferreira L.A. Novel vesicular and particulate drug delivery systems for topical treatment of acne. Expert Opin. Drug Deliv. 2008, 5:665-679.
165. Taepaiboon P., Rungsardthong U., Supaphol P. Vitamin-loaded electrospun cellulose acetate nanofiber mats as transdermal and dermal therapeutic agents of vitamin A acid and vitamin E. Eur. J. Pharm. Biopharm. 2007, 67:387-397.
166. Shah K.A., Date A.A., Joshi M.D., Patravale V.B. Solid lipid nanoparticles (SLN) of tretinoin: potential in topical delivery. Int. J. Pharm. 2007, 345:163-171.
167. Sato K., Matsumoto D., Iizuka F., Aiba-Kojima E., Machino C., Suga H., Watanabe-Ono A., Inoue K., Gonda K., Yoshimura K. A clinical trial of topical bleaching treatment with nanoscale tretinoin particles and hydroquinone for hyperpigmented skin lesions. Dermatol. Surg. 2007, 33:937-944.
168. Liu J., Hu W., Chen H., Ni Q., Xu H., Yang X. Isotretinoin-loaded solid lipid nanoparticles with skin targeting for topical delivery. Int. J. Pharm. 2007, 328:191-195.
169. Pople P.V., Singh K.K. Development and evaluation of topical formulation containing solid lipid nanoparticles of vitamin A. AAPS PharmSciTech 2006, 7:91.
170. Mukherjee S., Date A., Patravale V., Korting H.C., Roeder A., Weindl G. Retinoids in the treatment of skin aging: an overview of clinical efficacy and safety. Clin. Interv. Aging 2006, 1:327-348.
171. Yamaguchi Y., Nagasawa T., Nakamura N., Takenaga M., Mizoguchi M., Kawai S., Mizushima Y., Igarashi R. Successful treatment of photo-damaged skin of nano-scale atRA particles using a novel transdermal delivery. J. Control. Release 2005, 104:29-40.
172. Jenning V., Schäfer-Korting M., Gohla S. Vitamin A-loaded solid lipid nanoparticles for topical use: drug release properties. J. Control. Release 2000, 66:115-126.
173. Jenning V., Gysler A., Schäfer-Korting M., Gohla S.H. Vitamin A loaded solid lipid nanoparticles for topical use: occlusive properties and drug targeting to the upper skin. Eur. J. Pharm. Biopharm. 2000, 49:211-218.
174. Thielitz A., Gollnick H. Topical retinoids in acne vulgaris: update on efficacy and safety. Am. J. Clin. Dermatol. 2008, 9:369-381.
175. Kafi R., Kwak H.S., Schumacher W.E., Cho S., Hanft V.N., Hamilton T.A., King A.L., Neal J.D., Varani J., Fisher G.J., Voorhees J.J., Kang S. Improvement of naturally aged skin with vitamin A (retinol). Arch. Dermatol. 2007, 143:606-612.
176. Martin B., Meunier C., Montels D., Watts O. Chemical stability of adapalene and tretinoin when combined with benzoyl peroxide in presence and in absence of visible light and ultraviolet radiation. Br. J. Dermatol. 1998, 139:8-11.
177. Eskandar N., Simovic S., Prestidge C.A. Nanoparticle coated submicron emulsions: sustained in-vitro release and improved dermal delivery of all-trans-retinol. Pharm. Res. 2009, 26:1764-1775.
178. Zhao Y., Moddaresi M., Jones S.A., Brown M.B. A dynamic topical hydrofluoroalkane foam to induce nanoparticle modification and drug release in situ. Eur. J. Pharm. Biopharm. 2009, 72:521-528.
179. Moddaresi M., Brown M.B., Tamburic S., Jones S.A. The role of vehicle-nanoparticle interactions in topical drug delivery. Int. J. Pharm. 2010, 400:176-182.
180. Moddaresi M., Brown M.B., Tamburic S., Jones S.A. Tocopheryl acetate disposition in porcine and human skin when administered using lipid nanocarriers. J. Pharm. Pharmacol. 2010, 62:762-769.
181. Bronaugh R.L., Stewart R.F., Congdon E.R. Methods for in vitro percutaneous absorption studies. II. Animal models for human skin. Toxicol. Appl. Pharmacol. 1982, 62:481-488.
182. A.C. Green, Premature ageing of the skin in a Queensland population, Med. J. Aust., 155 (1991) 473-474, 477-478.
183. Bhalekar M.R., Pokharkar V., Madgulkar A., Patil N. Preparation and evaluation of miconazole nitrate-loaded solid lipid nanoparticles for topical delivery. AAPS PharmSciTech 2009, 10:289-296.
184. Jain J., Arora S., Rajwade J.M., Omray P., Khandelwal S., Paknikar K.M. Silver nanoparticles in therapeutics: development of an antimicrobial gel formulation for topical use. Mol. Pharm. 2009, 6:1388-1401.
185. Jung R., Kim Y., Kim H.S., Jin H.J. Antimicrobial properties of hydrated cellulose membranes with silver nanoparticles. J. Biomater. Sci. Polym. Ed. 2009, 20:311-324.
186. Keck C.M., Schwabe K. Silver-nanolipid complex for application to atopic dermatitis skin: rheological characterization, in vivo efficiency and theory of action. J. Biomed. Nanotechnol. 2009, 5:428-436.
187. Kim K.J., Sung W.S., Moon S.K., Choi J.S., Kim J.G., Lee D.G. Antifungal effect of silver nanoparticles on dermatophytes. J. Microbiol. Biotechnol. 2008, 18:1482-1484.
188. Passerini N., Gavini E., Albertini B., Rassu G., Di Sabatino M., Sanna V., Giunchedi P., Rodriguez L. Evaluation of solid lipid microparticles produced by spray congealing for topical application of econazole nitrate. J. Pharm. Pharmacol. 2009, 61:559-567.
189. Sanna V., Gavini E., Cossu M., Rassu G., Giunchedi P. Solid lipid nanoparticles (SLN) as carriers for the topical delivery of econazole nitrate: in-vitro characterization, ex-vivo and in-vivo studies. J. Pharm. Pharmacol. 2007, 59:1057-1064.
190. Sanna V., Mariani A., Caria G., Sechi M. Synthesis and evaluation of different fatty acid esters formulated into Precirol ATO-Based lipid nanoparticles as vehicles for topical delivery. Chem. Pharm. Bull. (Tokyo) 2009, 57:680-684.
191. Alt V., Bechert T., Steinrucke P., Wagener M., Seidel P., Dingeldein E., Domann E., Schnettler R. An in vitro assessment of the antibacterial properties and cytotoxicity of nanoparticulate silver bone cement. Biomaterials 2004, 25:4383-4391.
192. Fu J., Ji J., Fan D., Shen J. Construction of antibacterial multilayer films containing nanosilver via layer-by-layer assembly of heparin and chitosan-silver ions complex. J. Biomed. Mater. Res. A 2006, 79:665-674.
193. Borgers M. Mechanism of action of antifungal drugs, with special reference to the imidazole derivatives. Rev. Infect. Dis. 1980, 2:520-534.
194. Muller R.H., Radtke M., Wissing S.A. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv. Drug Deliv. Rev. 2002, 54(Suppl 1):S131-S155.
195. Souto E.B., Wissing S.A., Barbosa C.M., Muller R.H. Development of a controlled release formulation based on SLN and NLC for topical clotrimazole delivery. Int. J. Pharm. 2004, 278:71-77.
196. Trop M. The safety of nanocrystalline silver dressing on burns: a study of systemic silver absorption. Burns 2009, 35:306. (author reply 307).
197. Deng Z.J., Mortimer G., Schiller T., Musumeci A., Martin D., Minchin R.F. Differential plasma protein binding to metal oxide nanoparticles. Nanotechnology 2009, 20:455101.
198. Battah S., O'Neill S., Edwards C., Balaratnam S., Dobbin P., MacRobert A.J. Enhanced porphyrin accumulation using dendritic derivatives of 5-aminolaevulinic acid for photodynamic therapy: an in vitro study. Int. J. Biochem. Cell Biol. 2006, 38:1382-1392.
199. Chen H., Chang X., Du D., Liu W., Liu J., Weng T., Yang Y., Xu H., Yang X. Podophyllotoxin-loaded solid lipid nanoparticles for epidermal targeting. J. Control. Release 2006, 110:296-306.
200. Battah S., Balaratnam S., Casas A., O'Neill S., Edwards C., Batlle A., Dobbin P., MacRobert A.J. Macromolecular delivery of 5-aminolaevulinic acid for photodynamic therapy using dendrimer conjugates. Mol. Cancer Ther. 2007, 6:876-885.
201. Khandavilli S., Panchagnula R. Nanoemulsions as versatile formulations for paclitaxel delivery: peroral and dermal delivery studies in rats. J. Invest. Dermatol. 2007, 127:154-162.
202. Venuganti V.V., Perumal O.P. Effect of poly(amidoamine) (PAMAM) dendrimer on skin permeation of 5-fluorouracil. Int. J. Pharm. 2008, 361:230-238.
203. Venuganti V.V., Perumal O.P. Poly(amidoamine) dendrimers as skin penetration enhancers: influence of charge, generation, and concentration. J. Pharm. Sci. 2009, 98:2345-2356.
204. Zhao Q.H., Zhang Y., Liu Y., Wang H.L., Shen Y.Y., Yang W.J., Wen L.P. Anticancer effect of realgar nanoparticles on mouse melanoma skin cancer in vivo via transdermal drug delivery. Med. Oncol. 2010, 27:203-212.
205. Casas A., Battah S., Di Venosa G., Dobbin P., Rodriguez L., Fukuda H., Batlle A., MacRobert A.J. Sustained and efficient porphyrin generation in vivo using dendrimer conjugates of 5-ALA for photodynamic therapy. J. Control. Release 2009, 135:136-143.
206. Bourre L., Giuntini F., Eggleston I.M., Wilson M., MacRobert A.J. 5-Aminolaevulinic acid peptide prodrugs enhance photosensitization for photodynamic therapy. Mol. Cancer Ther. 2008, 7:1720-1729.
207. Canel C., Moraes R.M., Dayan F.E., Ferreira D. Podophyllotoxin. Phytochemistry 2000, 54:115-120.
208. Longstaff E., von Krogh G. Condyloma eradication: self-therapy with 0.15-0.5% podophyllotoxin versus 20-25% podophyllin preparations-an integrated safety assessment. Regul. Toxicol. Pharmacol. 2001, 33:117-137.
209. Puglia C., Bonina F., Castelli F., Micieli D., Sarpietro M.G. Evaluation of percutaneous absorption of the repellent diethyltoluamide and the sunscreen ethylhexyl p-methoxycinnamate-loaded solid lipid nanoparticles: an in-vitro study. J. Pharm. Pharmacol. 2009, 61:1013-1019.
210. Hoeller S., Sperger A., Valenta C. Lecithin based nanoemulsions: a comparative study of the influence of non-ionic surfactants and the cationic phytosphingosine on physicochemical behaviour and skin permeation. Int. J. Pharm. 2009, 370:181-186.
211. Tsujimoto H., Hara K., Tsukada Y., Huang C.C., Kawashima Y., Arakaki M., Okayasu H., Mimura H., Miwa N. Evaluation of the permeability of hair growing ingredient encapsulated PLGA nanospheres to hair follicles and their hair growing effects. Bioorg. Med. Chem. Lett. 2007, 17:4771-4777.
212. Elshafeey A.H., Kamel A.O., Fathallah M.M. Utility of nanosized microemulsion for transdermal delivery of tolterodine tartrate: ex-vivo permeation and in-vivo pharmacokinetic studies. Pharm. Res. 2009, 26:2446-2453.
213. So J.W., Kim S., Park J.S., Kim B.H., Jung S.H., Shin S.C., Cho C.W. Preparation and evaluation of solid lipid nanoparticles with JSH18 for skin-whitening efficacy. Pharm. Dev. Technol. 2010, 15:415-420.
214. Hasanovic A., Zehl M., Reznicek G., Valenta C. Chitosan-tripolyphosphate nanoparticles as a possible skin drug delivery system for aciclovir with enhanced stability. J. Pharm. Pharmacol. 2009, 61:1609-1616.
215. Kumar D., Aqil M., Rizwan M., Sultana Y., Ali M. Investigation of a nanoemulsion as vehicle for transdermal delivery of amlodipine. Pharmazie 2009, 64:80-85.
216. Uner M., Wissing S.A., Yener G., Muller R.H. Skin moisturizing effect and skin penetration of ascorbyl palmitate entrapped in solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) incorporated into hydrogel. Pharmazie 2005, 60:751-755.
217. Abramovic Z., Sustarsic U., Teskac K., Sentjurc M., Kristl J. Influence of nanosized delivery systems with benzyl nicotinate and penetration enhancers on skin oxygenation. Int. J. Pharm. 2008, 359:220-227.
218. Wang J.J., Liu K.S., Sung K.C., Tsai C.Y., Fang J.Y. Skin permeation of buprenorphine and its ester prodrugs from lipid nanoparticles: lipid emulsion, nanostructured lipid carriers and solid lipid nanoparticles. J. Microencapsul. 2009, 1-14.
219. Lin Y.K., Huang Z.R., Zhuo R.Z., Fang J.Y. Combination of calcipotriol and methotrexate in nanostructured lipid carriers for topical delivery. Int. J. Nanomedicine 2010, 5:117-128.
220. Berardesca E., Barbareschi M., Veraldi S., Pimpinelli N. Evaluation of efficacy of a skin lipid mixture in patients with irritant contact dermatitis, allergic contact dermatitis or atopic dermatitis: a multicenter study. Contact Dermat. 2001, 45:280-285.
221. Kim D.W., Hwang I.K., Yoo K.Y., Won C.K., Moon W.K., Won M.H. Coenzyme Q10 effects on manganese superoxide dismutase and glutathione peroxidase in the hairless mouse skin induced by ultraviolet B irradiation. Biofactors 2007, 30:139-147.
222. Kim S.T., Jang D.J., Kim J.H., Park J.Y., Lim J.S., Lee S.Y., Lee K.M., Lim S.J., Kim C.K. Topical administration of cyclosporin A in a solid lipid nanoparticle formulation. Pharmazie 2009, 64:510-514.
223. Lopes L.B., Ferreira D.A., de Paula D., Garcia M.T., Thomazini J.A., Fantini M.C., Bentley M.V. Reverse hexagonal phase nanodispersion of monoolein and oleic acid for topical delivery of peptides: in vitro and in vivo skin penetration of cyclosporin A. Pharm. Res. 2006, 23:1332-1342.
224. Stecova J., Mehnert W., Blaschke T., Kleuser B., Sivaramakrishnan R., Zouboulis C.C., Seltmann H., Korting H.C., Kramer K.D., Schäfer-Korting M. Cyproterone acetate loading to lipid nanoparticles for topical acne treatment: particle characterisation and skin uptake. Pharm. Res. 2007, 24:991-1000.
225. Azeem A., Ahmad F.J., Talegaonkar S. Exploration of skin permeation mechanism of frusemide with proniosomes. Pharmazie 2009, 64:735-740.
226. Barichello J.M., Morishita M., Takayama K., Nagai T. Absorption of insulin from pluronic F-127 gels following subcutaneous administration in rats. Int. J. Pharm. 1999, 184:189-198.
227. Tahara Y., Honda S., Kamiya N., Piao H., Hirata A., Hayakawa E., Fujii T., Goto M. A solid-in-oil nanodispersion for transcutaneous protein delivery. J. Control. Release 2008, 131:14-18.
228. Pathak P., Nagarsenker M. Formulation and evaluation of lidocaine lipid nanosystems for dermal delivery. AAPS PharmSciTech 2009, 10:985-992.
229. Kwon T.K., Kim J.C. In vitro skin permeation of monoolein nanoparticles containing hydroxypropyl beta-cyclodextrin/minoxidil complex. Int. J. Pharm. 2010, 392:268-273.
230. Zhao Y., Brown M.B., Jones S.A. The effects of particle properties on nanoparticle drug retention and release in dynamic minoxidil foams. Int. J. Pharm. 2010, 383:277-284.
231. Bhaskar K., Krishna Mohan C., Lingam M., Jagan Mohan S., Venkateswarlu V., Madhusudan Rao Y., Anbu J., Ravichandran V. Development of SLN and NLC enriched hydrogels for transdermal delivery of nitrendipine: in vitro and in vivo characteristics. Drug Dev. Ind. Pharm. 2009, 35:98-113.
232. Bhaskar K., Krishna Mohan C., Lingam M., Prabhakar Reddy V., Venkateswarlu V., Madhusudan Rao Y. Development of nitrendipine controlled release formulations based on SLN and NLC for topical delivery: in vitro and ex vivo characterization. Drug Dev. Ind. Pharm. 2008, 34:719-725.
233. Gulbake A., Jain A., Khare P., Jain S.K. Solid lipid nanoparticles bearing oxybenzone: in-vitro and in-vivo evaluation. J. Microencapsul. 2010, 27:226-233.
234. Klang V., Matsko N., Zimmermann A.M., Vojnikovic E., Valenta C. Enhancement of stability and skin permeation by sucrose stearate and cyclodextrins in progesterone nanoemulsions. Int. J. Pharm. 2010, 393:152-160.
235. Fang J.Y., Fang C.L., Liu C.H., Su Y.H. Lipid nanoparticles as vehicles for topical psoralen delivery: solid lipid nanoparticles (SLN) versus nanostructured lipid carriers (NLC). Eur. J. Pharm. Biopharm. 2008, 70:633-640.
236. Munster U., Nakamura C., Haberland A., Jores K., Mehnert W., Rummel S., Schaller M., Korting H.C., Zouboulis Ch C., Blume-Peytavi U., Schäfer-Korting M. RU 58841-myristate-prodrug development for topical treatment of acne and androgenetic alopecia. Pharmazie 2005, 60:8-12.
237. Dragicevic-Curic N., Scheglmann D., Albrecht V., Fahr A. Development of different temoporfin-loaded invasomes-novel nanocarriers of temoporfin: characterization, stability and in vitro skin penetration studies. Colloids Surf. B Biointerfaces 2009, 70:198-206.
238. Ziv-Polat O., Topaz M., Brosh T., Margel S. Enhancement of incisional wound healing by thrombin conjugated iron oxide nanoparticles. Biomaterials 2010, 31:741-747.
239. Liu W., Hu M., Xue C., Xu H., Yang X. Investigation of the carbopol gel of solid lipid nanoparticles for the transdermal iontophoretic delivery of triamcinolone acetonide acetate. Int. J. Pharm. 2008, 364:135-141.
240. Rastogi R., Anand S., Koul V. Flexible polymerosomes-an alternative vehicle for topical delivery. Colloids Surf. B Biointerfaces 2009, 72:161-166.
241. Jain N.K., Gupta U. Application of dendrimer-drug complexation in the enhancement of drug solubility and bioavailability. Expert Opin. Drug Metab. Toxicol. 2008, 4:1035-1052.
242. Nishiyama N., Morimoto Y., Jang W.D., Kataoka K. Design and development of dendrimer photosensitizer-incorporated polymeric micelles for enhanced photodynamic therapy. Adv. Drug Deliv. Rev. 2009, 61:327-338.
243. Kuchler S., Abdel-Mottaleb M., Lamprecht A., Radowski M.R., Haag R., Schäfer-Korting M. Influence of nanocarrier type and size on skin delivery of hydrophilic agents. Int. J. Pharm. 2009, 377:169-172.
244. Kuchler S., Herrmann W., Panek-Minkin G., Blaschke T., Zoschke C., Kramer K.D., Bittl R., Schäfer-Korting M. SLN for topical application in skin diseases-characterization of drug-carrier and carrier-target interactions. Int. J. Pharm. 2010, 390:225-233.
245. Kuchler S., Wolf N.B., Heilmann S., Weindl G., Helfmann J., Yahya M.M., Stein C., Schäfer-Korting M. 3D-wound healing model: influence of morphine and solid lipid nanoparticles. J. Biotechnol. 2010, 148:24-30.
246. Kuchler S., Radowski M.R., Blaschke T., Dathe M., Plendl J., Haag R., Schäfer-Korting M., Kramer K.D. Nanoparticles for skin penetration enhancement-a comparison of a dendritic core-multishell-nanotransporter and solid lipid nanoparticles. Eur. J. Pharm. Biopharm. 2009, 71:243-250.
247. Pardeike J., Hommoss A., Muller R.H. Lipid nanoparticles (SLN, NLC) in cosmetic and pharmaceutical dermal products. Int. J. Pharm. 2009, 366:170-184.
248. Caldorera-Moore M., Guimard N., Shi L., Roy K. Designer nanoparticles: incorporating size, shape and triggered release into nanoscale drug carriers. Expert Opin. Drug Deliv. 2010, 7:479-495.
249. Chen W., Meng F., Cheng R., Zhong Z. pH-Sensitive degradable polymersomes for triggered release of anticancer drugs: a comparative study with micelles. J. Control. Release 2010, 142:40-46.
250. Bower C.K., Sananikone S., Bothwell M.K., McGuire J. Activity losses among T4 lysozyme charge variants after adsorption to colloidal silica. Biotechnol. Bioeng. 1999, 64:373-376.
251. Goldberg M., Langer R., Jia X. Nanostructured materials for applications in drug delivery and tissue engineering. J. Biomater. Sci. Polym. Ed. 2007, 18:241-268.
252. Borm P.J., Kreyling W. Toxicological hazards of inhaled nanoparticles-potential implications for drug delivery. J. Nanosci. Nanotechnol. 2004, 4:521-531.
253. Geiser M., Kreyling W.G. Deposition and biokinetics of inhaled nanoparticles. Part. Fibre Toxicol. 2010, 7:2.
254. Wang H.K., Duffy A.A., Broker T.R., Chow L.T. Robust production and passaging of infectious HPV in squamous epithelium of primary human keratinocytes. Genes Dev. 2009, 23:181-194.
255. Lv Q., Yu A., Xi Y., Li H., Song Z., Cui J., Cao F., Zhai G. Development and evaluation of penciclovir-loaded solid lipid nanoparticles for topical delivery. Int. J. Pharm. 2009, 372:191-198.
256. Sanchez W.Y., Prow T.W., Sanchez W.H., Grice J.E., Roberts M.S. Analysis of the metabolic deterioration of ex vivo skin from ischemic necrosis through the imaging of intracellular NAD(P)H by multiphoton tomography and fluorescence lifetime imaging microscopy. J. Biomed. Opt. 2010, 15:046008.
257. Bird D.K., Yan L., Vrotsos K.M., Eliceiri K.W., Vaughan E.M., Keely P.J., White J.G., Ramanujam N. Metabolic mapping of MCF10A human breast cells via multiphoton fluorescence lifetime imaging of the coenzyme NADH. Cancer Res. 2005, 65:8766-8773.